ABSTRACT
Alveolar soft part sarcoma (ASPS) is a rare mesenchymal malignancy typically found in the extremities or chest of young adults. We present a case of an alveolar soft part sarcoma arising in the endocervix of a 38-year-old premenopausal woman. This cancer was treated by extrafascial hysterectomy. No evidence of metastatic disease was found after extensive surgical staging. Since treatment, she has since remained disease-free for more than 5 years without additional therapy. This is the second case of ASPS arising in the endocervix of which we are aware. Our observations suggest simple hysterectomy suffices for optimal clinical management of cervical ASPS and that surgical staging of this disease offers little prognostic benefit.
Subject(s)
Sarcoma, Alveolar Soft Part/diagnosis , Uterine Cervical Neoplasms/diagnosis , Adult , Dilatation and Curettage , Female , Humans , Hysterectomy , Metrorrhagia , Neoplasm Staging , Ovariectomy , Sarcoma, Alveolar Soft Part/pathology , Sarcoma, Alveolar Soft Part/surgery , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/surgeryABSTRACT
The in vivo feasibility of the previously established ID8 and ID8-VEGF ovarian cancer models for non-viral IL-12 gene delivery by itself or in combination with paclitaxel chemotherapy, was investigated in C57BL/6 black mice. The syngeneic mouse ovarian epithelium (MOSE) cancer cell line and its more aggressive variant, a VEGF-modified strain, were used to perform these experiments. Tumor growth and survival were observed in C57/BL6 mice, inoculated with both ID8 substrains. The superiority of IL-12 gene therapy in comparison to conventional paclitaxel chemotherapy in terms of tumor size and survival was demonstrated.
Subject(s)
Angiogenesis Inhibitors/therapeutic use , Antineoplastic Agents, Phytogenic/therapeutic use , Disease Models, Animal , Genetic Therapy , Interleukin-12/therapeutic use , Ovarian Neoplasms/therapy , Paclitaxel/therapeutic use , Angiogenesis Inhibitors/genetics , Animals , Combined Modality Therapy , Epithelial Cells/drug effects , Epithelial Cells/pathology , Female , Humans , Interleukin-12/genetics , Mice , Mice, Inbred C57BL , Mice, Nude , Ovarian Neoplasms/pathology , Plasmids/genetics , Polymers/chemistry , Survival Rate , Tumor Cells, Cultured , Vascular Endothelial Growth Factor A/geneticsABSTRACT
Attempts to develop novel immunotherapeutic mouse models have been hampered by the lack of an adequate in vivo system. This study was performed to establish an immunocompetent mouse model for the testing of immunotherapy concepts. The in vivo system was based on a svngeneic mouse ovarian surface epithelium (MOSE) cancer, physiologically and biologically closely resembling human epithelial ovarian cancer. In addition, a more aggressive variant containing a mutated form of vascular epithelial growth factor was also evaluated. The growth patterns of these ovarian cancer cells in mice were compared to the established, highly aggressive 4T1 breast cancer model. A clinically-relevant tool for the study of different growth patterns in ovarian cancer, with potential significance for the development of novel immunological methods, was successfully developed.
